Wortmannin-Rapamycin Conjugate Chemical Properties

storage temp. 

Store at -20°C

solubility 

DMF: 30 mg/ml; DMSO: 20 mg/ml; Ethanol: 5 mg/ml

form 

A crystalline solid

Wortmannin-Rapamycin Conjugate Usage And Synthesis

Description

Phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) act synergistically in promoting cancer. Wortmannin is a potent inhibitor of PI3K enzymes, while rapamycin blocks mTOR Complex 1 TORC1. Wortmannin-rapamycin conjugate consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker. Hydrolysis of the prodrug linker in vivo releases the inhibitors. The wortmannin-rapamycin conjugate inhibits the growth of HT-29 colon tumors and A498 renal tumors in mice better than rapamycin alone. Also, the conjugate, when given in combination with the VEGF-blocker bevacizumab, produces substantial regression of larger A498 tumors. Finally, the wortmannin-rapamycin conjugate is tolerated better than an equivalent mixture of the inhibitors.

Wortmannin-Rapamycin Conjugate(1067892-47-0)Related Product Information

• 6-amino-8-[3-bromo-5-methoxy-4-(prop-2-en-1-yloxy)phenyl]-8H-[1,3]dioxolo[4,5-g]chromene-7-carbonitrile
• 8H-1,3-Dioxolo[4,5-g][1]benzopyran-7-carbonitrile, 6-amino-8-(3-bromo-4,5-dimethoxyphenyl)-
• Wnt/β-catenin agonist 1
• 3-Isoxazolecarboxamide, 5-(2-furanyl)-N-[2-(1H-pyrazol-1-yl)ethyl]-
• 3-Isoxazolecarboxamide, 5-(4-fluorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]-
• Wnt pathway activator 2